CF PharmTech will convene its annual general meeting (AGM) on 26 June 2026 in Suzhou to seek shareholder approval on nine key resolutions that shape its next operating cycle and capital strategy.
Key items slated for approval
1. 2025 Performance Reporting • Audited consolidated financial statements and the full 2025 annual report—already cleared by the Board on 30 March 2026—will be tabled for shareholder endorsement.
2. Board and Supervisory Committee Renewal • Eleven directors are proposed for the fourth three-year board term, including five executive directors (notably co-founder and CEO Dr Liang Bill Wenqing) and four independent non-executive directors. • Three supervisors are nominated for the fourth Supervisory Committee term.
3. Auditor Re-appointment • Ernst & Young is recommended to continue as external auditor for FY 2026 with an expected audit fee of RMB 2.20 million–RMB 2.80 million (USD 0.30 million–USD 0.38 million).
4. Expanded H-Share Award Scheme • The 2025 H Share Award Trust Scheme is to be amended to add “Service Providers” as eligible participants. • Scheme parameters—3% cap of issued H shares (up to 9.07 million shares) and 1% individual limit—remain unchanged. • Vesting will explicitly require at least a “Satisfactory” internal appraisal for employees; forfeiture rules for service contracts are clarified.
5. Capital Management Authorities • Issuance Mandate: Board may allot, issue or transfer up to 20% of issued H shares (about 60.20 million shares) within 12 months after approval. • Share Repurchase Mandate: Board may buy back up to 10% of issued H shares (about 30.10 million shares) over the same period. Any repurchased shares can be cancelled or held as treasury stock. • The company currently holds 1.22 million treasury shares and has repurchased 1.22 million H shares since December 2025.
Key timetable and participation details
• Register closure: 23–26 June 2026 (both days inclusive); record date 26 June 2026. • Proxy forms must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 25 June 2026. • Voting will be conducted by poll; 2.96 million scheme-reserved H shares and 1.22 million treasury shares carry no voting rights at the AGM.
If all resolutions pass, CF PharmTech will enter its fourth board cycle, broaden equity incentives to strategic partners, and secure flexibility for both fundraising and buy-backs in the coming year.